← All stocks

Alnylam Pharmaceuticals, Inc.

ALNYPharmaceuticalsLatest filing used: 2026-10-29Filings on SEC EDGAR ↗

Fast grower

Fair value per share

No filings-based value

The filings alone are probably missing something here: the company's typical cash earnings in the filings are negative.

Last close

$165.02

Nov 13, 2026

How we decide

Ten years of results

Revenue

$3.7B in FY2025, up 65% on the year before

FY2016: $47MFY2017: $90MFY2018: $75MFY2019: $220MFY2020: $493MFY2021: $844MFY2022: $1.0BFY2023: $1.8BFY2024: $2.2BFY2025: $3.7B$2B$4BFY16FY19FY22FY25$3.7B
Show as table
YearRevenue
FY2016$47M
FY2017$90M
FY2018$75M
FY2019$220M
FY2020$493M
FY2021$844M
FY2022$1.0B
FY2023$1.8B
FY2024$2.2B
FY2025$3.7B

Cash earnings as a share of sales

17.4% of sales in FY2025

FY2018: -1055.2%FY2019: -408.8%FY2020: -148.3%FY2021: -77.2%FY2022: -71.3%FY2023: -7.8%FY2024: 0.7%FY2025: 17.4%-1055%-518%20%FY16FY19FY22FY2517%
Show as table
YearCash earnings as a share of sales
FY2016–
FY2017–
FY2018-1055.2%
FY2019-408.8%
FY2020-148.3%
FY2021-77.2%
FY2022-71.3%
FY2023-7.8%
FY20240.7%
FY202517.4%

Shares outstanding

Share count rose 23% over 9 years

FY2019: 109MFY2020: 115MFY2021: 118MFY2022: 122MFY2023: 125MFY2024: 128MFY2025: 135M075M150MFY16FY19FY22FY25134.7M
Show as table
YearShares outstanding
FY2016–
FY2017–
FY2018–
FY2019109M
FY2020115M
FY2021118M
FY2022122M
FY2023125M
FY2024128M
FY2025135M

No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-10-29. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13.